Radius Health Inc. (RDUS)’s Financial Results Comparing With Vaccinex Inc. (NASDAQ:VCNX)

Radius Health Inc. (NASDAQ:RDUS) and Vaccinex Inc. (NASDAQ:VCNX) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Radius Health Inc. 99.24M 8.61 221.34M -5.57 0.00
Vaccinex Inc. N/A 73.48 24.47M -2.13 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Radius Health Inc. and Vaccinex Inc.


Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Radius Health Inc. -223.04% -155% -67.2%
Vaccinex Inc. 0.00% 0% 0%


The Current Ratio and Quick Ratio of Radius Health Inc. are 5.5 and 5.4 respectively. Its competitor Vaccinex Inc.’s Current Ratio is 4.8 and its Quick Ratio is 4.8. Radius Health Inc. can pay off short and long-term obligations better than Vaccinex Inc.

Analyst Ratings

In next table is given Radius Health Inc. and Vaccinex Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Radius Health Inc. 0 1 2 2.67
Vaccinex Inc. 0 0 0 0.00

The consensus price target of Radius Health Inc. is $43.67, with potential upside of 133.78%.

Insider & Institutional Ownership

Roughly 0% of Radius Health Inc. shares are held by institutional investors while 2.1% of Vaccinex Inc. are owned by institutional investors. Insiders held 0.1% of Radius Health Inc. shares. Comparatively, Vaccinex Inc. has 84.78% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Radius Health Inc. 1.69% 8.98% 26.09% -3.21% -46.96% 20.74%
Vaccinex Inc. -5.56% -12.19% -21.44% -59.06% 0% 16.6%

For the past year Radius Health Inc. has stronger performance than Vaccinex Inc.


Vaccinex Inc. beats Radius Health Inc. on 6 of the 10 factors.

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. Its product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. The company is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer. It has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Lonza Group Ltd.; Novartis Pharmaceuticals; and Takeda Pharmaceutical Company Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington's disease. The company's preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.